Aurobindo Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Aurobindo Pharma announced that CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Central Drugs Standard Control Organization (CDSCO) has granted Marketing Authorisation under Form CT 23 for Bevqolva?, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ's facility in Hyderabad and marketing of Bevqolva? in 100 mg/4mL and 400 mg/16 mL vial presentations.

Aurobindo Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1514.7, up 1.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.27% on the day, quoting at 23710.55. The Sensex is at 75385.46, up 1.04%. Aurobindo Pharma Ltd has risen around 10.25% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 9.11% in last one month and is currently quoting at 23896.05, up 2.44% on the day. The volume in the stock stood at 7.76 lakh shares today, compared to the daily average of 14.11 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 1522.1, up 1.16% on the day. Aurobindo Pharma Ltd is up 24.47% in last one year as compared to a 5.39% drop in NIFTY and a 13.06% drop in the Nifty Pharma index.

The PE of the stock is 40.57 based on TTM earnings ending December 25.

Powered by Capital Market - Live News

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 21 May 2026.

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana from 28 January to 10 February 2026. At the end of the inspection, a 'Form 483' was issued with a total of 9 observations.

The Unit has now received Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI). FDA has concluded that this inspection is now closed.